Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07AOO
|
|||
| Former ID |
DCL000626
|
|||
| Drug Name |
Rilotumumab
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Grade IV malignant glioma [ICD-11: 2A00.0; ICD-10: C71; ICD-9: 191] | Discontinued in Phase 2 | [1], [2] | |
| Company |
Amgen
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7986). | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015060) | |||
| REF 3 | Clinical pipeline report, company report or official report of Amgen (2009). | |||
| REF 4 | AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6735-42. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.